TROG Cancer Research
Members Login   CQMS Login

NEW PROPOSALS

New Proposal applications are accepted for consideration at any time throughout the year.

Four types of New Proposals are accepted by TROG:

  • Category A: An investigator-initiated new proposal which can be submitted by a full TROG member, which will be carried out under the auspices of TROG.
  • Category B: An existing trial or new trial concept submitted by a full TROG member on behalf of an international trials organisation and where TROG would fulfil the role of the ANZ sponsor. The trial is carried out under the joint auspices of TROG and the group concerned. 
     
  • Category C: A trial initiated and sponsored by other trials organisation and is for collaboration with TROG.
     
  • Category D: An investigator-initiated project or registry that involves data capture, data mining or secondary analysis.

Submission process:

  1. Complete the online New Proposal application
    Note: 
     - you can stop the survey at any time and return at a later date to complete it, a survey link and return code will be provided if requested
     - a word version of the application is available for download to aid in drafting the proposal 
  2. Ensure that any supporting documentation has been uploaded, if applicable
  3. Submit the form by clicking 'Submit' on the last page of the application
  4. Once a new proposal has been submitted, it will be forward to the TROG Operations Executive committee for initial review 
     - a member of the TROG trial development team will be in contact after the initial review. See the TROG STUDY PATHWAY for further details. 

If you have any questions regarding the application or the New Proposal Pathway please contact tsc@trog.com.au or +61 2 40143910.


 

For detailed information on the progression of trials through TROGs trial timeline please refer to the TROG STUDY PATHWAY and TROG Policy Statement TPS E3 Guidelines on the Policy statements page.

 


 

PLEASE NOTE: In addition to the above, TROG also provides other Fee-For-Services, such as Radiotherapy Quality Assurance, Trial Management etc. Please contact TROG CEO, Susan.Goode@trog.com.au, for further details.  

Winner – 'Innovation in Cancer Clinical Trials' Award, 2013 NSW Premier’s Awards for Outstanding Cancer Research


Latest News

  • 15 May 2020

    The diagnosis of ductal carcinoma in situ (DCIS) of the breast has increased substantially due to mammographic screening, and now accounts for 25 per cent of screen-detected breast cancer. Over 1,600 women are diagnosed with DCIS in Australia every year. However, unlike invasive breast cancer, there are limited knowledge and experience for patients and clinicians to draw on when this now common diagnosis of DCIS is made.

  • 15 Apr 2020

    Prostate cancer is one of the most common cancers amongst men, with one in six men diagnosed before their 85th birthday (Cancer Australia). In fact, in 2019 alone over 19,000 men in Australia were diagnosed with prostate cancer.

  • 06 Apr 2020

    p style="text-align: center;">_ src="/sitefiles/trogcomau/trog_team_2020.jpg" style="height: 333px; width: 500px;" />   covid-19 and the regulations around social distancing has affected an increasing number of events across australia, including the yearly gathering of radiation...

  • 01 Apr 2020

    The coronavirus health pandemic is a challenging time for us all – personally and professionally. We know that the changes and safety precautions required as a result of the pandemic have had significant impacts on the way we operate clinical trials – those that are underway, set t...

  • 15 Jan 2020

    _ src="/sitefiles/trogcomau/fbp_0378_large.jpg" /> new research by the university of new south wales (unsw), presented at the clinical oncology society of australia’s (cosa) annual scientific meeting (asm) found that increased use of radiation therapy for prostate cancer patients c...

  • 13 Sep 2019

    trog cancer research will work with clinicians at townsville hospital, as well as other national experts, to implement a research program aimed at understanding how to best use new mri linac technology to benefit cancer patients. img src="/sitefiles/trogcomau/tro_trog_cancer_resear...

  • 09 Sep 2019

    TROG Cancer Research is currently in the final year of their 2017-2019 strategic plan. On Friday 2 August 2019, we held a strategic planning meeting with key stakeholders to discuss the direction and focus for the upcoming three years.  The workshop facilitated by Ms Alison Evans, Hea...

  • 03 Sep 2019

    trog cancer research are proud to announce that we have two new additions to the trog cancer research board of directors. joining our team is professor annette haworth and denis byron. appointed as a non-radiation oncology director, annette is an accredited medical physicist wh...